Human Immunodeficiency Virus- Market Insights, Epidemiology and Market Forecast 2028

Report Summary

"Human Immunodeficiency Virus- Market Insights, Epidemiology and Market Forecast 2028" report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering United States, EUS (Germany, France, Italy, Spain and the United Kingdom), Japan

Study Period: 2016-2028

Human Immunodeficiency Virus Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Human Immunodeficiency Virus in the US, Europe, and Japan are also provided in the report.

Human Immunodeficiency Virus Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to the account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

Human Immunodeficiency Virus Product Profiles & Analysis

This part of the Human Immunodeficiency Virus report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

Human Immunodeficiency Virus Market Outlook

The Human Immunodeficiency Virus market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

Human Immunodeficiency Virus Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

Human Immunodeficiency Virus Report Insights

Patient Population in Human Immunodeficiency Virus

Therapeutic Approaches in Human Immunodeficiency Virus

Human Immunodeficiency Virus Pipeline Analysis

Human Immunodeficiency Virus Market Size and Trends

Human Immunodeficiency Virus Market Opportunities

Impact of upcoming Therapies in Human Immunodeficiency Virus

Human Immunodeficiency Virus Report Key Strengths

10 Year Forecast

P&M Coverage

Epidemiology Segmentation

Drugs Uptake

Highly Analyzed Market

Key Cross Competition

Human Immunodeficiency Virus Report Assessment

Current Treatment Practices in Human Immunodeficiency Virus

Unmet Needs in Human Immunodeficiency Virus

Detailed Human Immunodeficiency Virus Pipeline Product Profiles

Market Attractiveness

Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Human Immunodeficiency Virus market

Organize sales and marketing efforts by identifying the best opportunities for Human Immunodeficiency Virus market

To understand the future market competition in the Human Immunodeficiency Virus market.

Note: We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.

Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
Table of Contents

1 Key Insights

2 Human Immunodeficiency Virus Market Overview at a Glance
   • 2.1 Market Share (%) Distribution of Human Immunodeficiency Virus in 2018
   • 2.2 Market Share (%) Distribution of Human Immunodeficiency Virus in 2028

3 Human Immunodeficiency Virus: Disease Background and Overview
   • 3.1 Introduction
   • 3.2 Symptoms
   • 3.3 Etiology
   • 3.4 Risk Factor
   • 3.5 Pathophysiology
   • 3.6 Diagnosis
   • 3.7 Treatment

4 Epidemiology and Patient Population
   • 4.1 Key Findings
   • 4.2 Total Prevalent/Incident Patient Population of Human Immunodeficiency Virus in 7MM
   • 4.3 Total Prevalent Population of Human Immunodeficiency Virus in 7MM – By Countries

5 Epidemiology of Human Immunodeficiency Virus by Countries (2016-2028)
   • 5.1 United States- Epidemiology (2016-2028)
     ■ 5.1.1 Assumptions and Rationale
     ■ 5.1.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in the United States
     ■ 5.1.3 Sub-Type Specific cases of Human Immunodeficiency Virus in the United States
     ■ 5.1.4 Sex- Specific Cases of Human Immunodeficiency Virus in the United States
     ■ 5.1.5 Diagnosed Cases of Human Immunodeficiency Virus in the United States
     ■ 5.1.6 Treatable Cases of Human Immunodeficiency Virus
   • 5.2 EU5 Countries
     ■ 5.2.1 Germany
       ■ 5.2.1.1 Assumptions and Rationale
       ■ 5.2.1.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in Germany
       ■ 5.2.1.3 Sub-Type Specific cases of Human Immunodeficiency Virus in Germany
       ■ 5.2.1.4 Sex- Specific Cases of Human Immunodeficiency Virus in Germany
       ■ 5.2.1.5 Diagnosed Cases of Human Immunodeficiency Virus in Germany
       ■ 5.2.1.6 Treatable Cases of Human Immunodeficiency Virus
     ■ 5.2.2 France
       ■ 5.2.2.1 Assumptions and Rationale
       ■ 5.2.2.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in France
       ■ 5.2.2.3 Sub-Type Specific cases of Human Immunodeficiency Virus in France
       ■ 5.2.2.4 Sex- Specific Cases of Human Immunodeficiency Virus in France
       ■ 5.2.2.5 Diagnosed Cases of Human Immunodeficiency Virus in France
       ■ 5.2.2.6 Treatable Cases of Human Immunodeficiency Virus
     ■ 5.2.3 Italy
       ■ 5.2.3.1 Assumptions and Rationale
       ■ 5.2.3.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in Italy
       ■ 5.2.3.3 Sub-Type Specific cases of Human Immunodeficiency Virus in Italy
       ■ 5.2.3.4 Sex- Specific Cases of Human Immunodeficiency Virus in Italy
       ■ 5.2.3.5 Diagnosed Cases of Human Immunodeficiency Virus in Italy
       ■ 5.2.3.6 Treatable Cases of Human Immunodeficiency Virus
     ■ 5.2.4 Spain
       ■ 5.2.4.1 Assumptions and Rationale
       ■ 5.2.4.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in Spain
       ■ 5.2.4.3 Sub-Type Specific cases of Human Immunodeficiency Virus in Spain
       ■ 5.2.4.4 Sex- Specific Cases of Human Immunodeficiency Virus in Spain
       ■ 5.2.4.5 Diagnosed Cases of Human Immunodeficiency Virus in Spain
       ■ 5.2.4.6 Treatable Cases of Human Immunodeficiency Virus
     ■ 5.2.5 United Kingdom
       ■ 5.2.5.1 Assumptions and Rationale
       ■ 5.2.5.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in the United Kingdom
       ■ 5.2.5.3 Sub-Type Specific cases of Human Immunodeficiency Virus in the United Kingdom
       ■ 5.2.5.4 Sex- Specific Cases of Human Immunodeficiency Virus in the United Kingdom
       ■ 5.2.5.5 Diagnosed Cases of Human Immunodeficiency Virus in the United Kingdom
       ■ 5.2.5.6 Treatable Cases of Human Immunodeficiency Virus
     ■ 5.3 Japan
       ■ 5.3.1 Assumptions and Rationale
       ■ 5.3.2 Prevalent/Incident Cases of Human Immunodeficiency Virus in Japan
       ■ 5.3.3 Sub-Type Specific cases of Human Immunodeficiency Virus in Japan
       ■ 5.3.4 Sex- Specific Cases of Human Immunodeficiency Virus in Japan
       ■ 5.3.5 Diagnosed Cases of Human Immunodeficiency Virus in Japan
       ■ 5.3.6 Treatable Cases of Human Immunodeficiency Virus

6 Current Treatment & Medical practices
   • 6.1 Treatment Algorithm
   • 6.2 Treatment Guidelines

7 Unmet Needs

8 Marketed Product
   • 8.1 Drug A: Company 1
     ■ 8.1.1 Drug Description
8.1.2 Mechanism of Action
8.1.3 Clinical Trials Details
8.1.4 Advantages & Disadvantages
8.1.5 Safety and Efficacy
8.1.6 Product Profile

8.2 Drug B: Company 2
8.2.1 Drug Description
8.2.2 Mechanism of Action
8.2.3 Clinical Trials Details
8.2.4 Advantages & Disadvantages
8.2.5 Safety and Efficacy
8.2.6 Product Profile

8.3 Drug C: Company 3
8.3.1 Drug Description
8.3.2 Mechanism of Action
8.3.3 Clinical Trials Details
8.3.4 Advantages & Disadvantages
8.3.5 Safety and Efficacy
8.3.6 Product Profile

8.4 Drug D: Company 4
8.4.1 Drug Description
8.4.2 Mechanism of Action
8.4.3 Clinical Trials Details
8.4.4 Advantages & Disadvantages
8.4.5 Safety and Efficacy
8.4.6 Product Profile

8.5 Drug E: Company 5
8.5.1 Drug Description
8.5.2 Mechanism of Action
8.5.3 Clinical Trials Details
8.5.4 Advantages & Disadvantages
8.5.5 Safety and Efficacy
8.5.6 Product Profile

8.6 : Company 6
8.6.1 Drug Description
8.6.2 Mechanism of Action
8.6.3 Clinical Trials Details
8.6.4 Advantages & Disadvantages
8.6.5 Safety and Efficacy
8.6.6 Product Profile

8.7 : Company 7
8.7.1 Drug Description
8.7.2 Mechanism of Action
8.7.3 Clinical Trials Details
8.7.4 Advantages & Disadvantages
8.7.5 Safety and Efficacy
8.7.6 Product Profile

8.8 : Company 8
8.8.1 Drug Description
8.8.2 Mechanism of Action
8.8.3 Clinical Trials Details
8.8.4 Advantages & Disadvantages
8.8.5 Safety and Efficacy
8.8.6 Product Profile

9 Emerging Drugs
9.1 Key Cross Competition
9.2 Emerging company
9.2.1 Emerging Drug A: Company 5
9.2.2 Emerging Drug B: Company 6
9.2.3 Emerging Drug C: Company 7
9.2.4 Emerging Drug D: Company 8
9.2.5 Emerging Drug E: Company 9
9.2.5.1 Other Development Activities
9.2.5.2 Clinical Development
9.2.5.3 Clinical Trials Information
9.2.5.4 Safety and Efficacy
9.2.5.5 Advantages and Disadvantages
9.2.5.6 Product Profile

10 7MM Market Analysis
10.1 7MM Market Size of Human Immunodeficiency Virus
10.2 7MM Percentage Share of Drugs Marketed for Human Immunodeficiency Virus
10.3 7MM Market Sales of Human Immunodeficiency Virus by Products

11 The United States Market Outlook
11.1 Market Size of Human Immunodeficiency Virus in United States
11.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in United States
11.3 Market Sales of Human Immunodeficiency Virus by Products in United States
11.4 Analysis of Upcoming Therapies and Impact on the Market

12 EU5 Countries Market Outlook
12.1 Market Size of Human Immunodeficiency Virus in EU5
12.2 Market Size of Human Immunodeficiency Virus in Germany
12.2.1 Market Size of Human Immunodeficiency Virus in Germany
12.2.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in Germany
12.2.3 Market Sales of Human Immunodeficiency Virus by Products in Germany
12.2.4 Analysis of Upcoming Therapies and Impact on the Market
12.3 Market Size of Human Immunodeficiency Virus in France
12.3.1 Market Size of Human Immunodeficiency Virus in France
12.3.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in France
12.3.3 Market Sales of Human Immunodeficiency Virus by Products in France
12.3.4 Analysis of Upcoming Therapies and Impact on the Market
12.4 Market Size of Human Immunodeficiency Virus in Italy
12.4.1 Market Size of Human Immunodeficiency Virus in Italy
12.4.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in Italy
12.4.3 Market Sales of Human Immunodeficiency Virus by Products in Italy
12.4.4 Analysis of Upcoming Therapies and Impact on the Market
12.5 Market Size of Human Immunodeficiency Virus in Spain
12.5.1 Market Size of Human Immunodeficiency Virus in Spain
12.5.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in Spain
12.5.3 Market Sales of Human Immunodeficiency Virus by Products in Spain
12.5.4 Analysis of Upcoming Therapies and Impact on the Market
12.6 Market Size of Human Immunodeficiency Virus in United Kingdom
12.6.1 Market Size of Human Immunodeficiency Virus in United Kingdom
12.6.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in United Kingdom
12.6.3 Market Sales of Human Immunodeficiency Virus by Products in United Kingdom
12.6.4 Analysis of Upcoming Therapies and Impact on the Market

13 The Japan Market Outlook
13.1 Market Size of Human Immunodeficiency Virus in Japan
13.2 Percentage Share of Drugs Marketed for Human Immunodeficiency Virus in Japan
13.3 Market Sales of Human Immunodeficiency Virus by Products in Japan
13.4 Analysis of Upcoming Therapies and Impact on the Market

14 Cost Analysis of Human Immunodeficiency Virus
15 Generic Competition in Human Immunodeficiency Virus Market
16 Market Drivers
17 Market Barriers
18 Report Methodology
18.1 Methodology/Research Approach
18.2 Data Source
18.2.1 Secondary Sources